Erlotinib HCL (Tarceva(R)) Induced Radiation Recall Dermatitis / 대한피부과학회지
Korean Journal of Dermatology
;
: 872-875, 2010.
Article
in Korean
| WPRIM
| ID: wpr-63103
ABSTRACT
Erlotinib (Tarceva(R)) is a new anti-cancer agent that acts by inhibiting epidermal growth factor receptor (EGFR) signal transduction. It is currently used in the treatment of advanced stage non-small cell lung cancer and pancreatic cancer. A patient consulted our clinic and she had erythematous patches and vesicles on the submandibular area. She had taken erlotinib for the treatment of recurred lung cancer for 2 weeks. We report here on a case of radiation recall dermatitis that was induced by erlotinib in a 69-year-old woman who was previously irradiated on her submandibular area.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pancreatic Neoplasms
/
Quinazolines
/
Radiodermatitis
/
Signal Transduction
/
Carcinoma, Non-Small-Cell Lung
/
ErbB Receptors
/
Erlotinib Hydrochloride
/
Lung Neoplasms
Limits:
Aged
/
Female
/
Humans
Language:
Korean
Journal:
Korean Journal of Dermatology
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS